dr. reddy's labs glp-1 receptor agonist weight management diabetes treatments Laboratories launches India's first DCGI-approved Semaglutide injection 'Obeda' for type 2 Walking on 'Thin' Ice: DHC
Description
The insulin-promoting impact of GLP-1, its putative role as a satiety factor, and greater fasting and postprandial NEFA levels may impede nutrition-mediated secretion, according to two clinical trials in patients with simple obesity [116]
Both hormones are rapidly released after ingestion, apparently under neural control, and stimulate insulin production in pancreatic cells in a glucose-dependent manner
Use of this information is at your own risk, and we are not liable for any outcomes resulting from its use.
Endocrinology 2000
Consensus of Chinese experts on oral hypoglycemic drugs combined with initial insulin in the treatment of type 2 diabetes mellitus
Gaeckler et al
